Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma

Laura Bonanno, Marco Schiavon, Giorgia Nardo, Roberta Bertorelle, Laura Bonaldi, Alessandra Galligioni, Stefano Indraccolo, Giulia Pasello, R. E A Federico, Adolfo Favaretto

Research output: Contribution to journalArticlepeer-review


Background/Aim: Gefitinib and erlotinib were shown to be particularly effective in a clinically selected subpopulation of non-small cell lung cancer patients (NSCLC): adenocarcinoma histology, non-smoking status, Asian origin and female gender have been associated with improved clinical benefit compared to the unselected NSCLC population. The aim of the present study was to investigate the prognostic and predictive role of EGFR and KRAS analysis in advanced lung adenocarcinomas, selected according to clinical features associated to better response to EGFR tyrosine kinase inhibitors (TKIs), namely female gender and non-smoker or former light smoker status. Patients and Methods: EGFR and KRAS mutations and EGFR FISH status were assessed in 67 surgical samples. Results: EGFR and KRAS mutations were found in 16 (26.7%) and 12 (17.9%) patients, respectively. FISH analysis was positive in 34 (56.7%) patients. EGFRmutated patients showed significantly longer survival when treated with EGFR TKIs (p=0.002, hazard ratio (HR)=0.036, 95% confidence interval (CI): 0.004 -0.303). KRAS mutations was found to be an independent negative prognostic factor in multivariate analysis (p=0.008, HR=3.52, 95%CI: 1.39-8.9). The prognostic value of EGFR FISH status was not confirmed in multivariate analysis (p=0.048, HR=0.47, 95%CI: 0.22-0.99). Conclusion: In a group of clinically selected patients, EGFR and KRAS analysis was able to define distinct molecular subsets of lung adenocarcinoma.

Original languageEnglish
Pages (from-to)5121-5128
Number of pages8
JournalAnticancer Research
Issue number12
Publication statusPublished - Dec 2010


  • Chemotherapy
  • Egfr gene copy number
  • Egfr tkis treatment
  • KRAS
  • Prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma'. Together they form a unique fingerprint.

Cite this